A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors-Reference-Cited by-同舟云学术

A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors

Published:2019-12-25 Issue:4 Volume:67 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Qayed Muna¹²,Cash Thomas¹²^ORCID,Tighiouart Mourad³,MacDonald Tobey J.¹²,Goldsmith Kelly C.¹²,Tanos Rachel²,Kean Leslie⁴,Watkins Benjamin¹²,Suessmuth Yvonne²,Wetmore Cynthia⁵,Katzenstein Howard M.⁶^ORCID

Affiliation:

1. Aflac Cancer and Blood Disorders CenterChildren's Healthcare of Atlanta Atlanta Georgia

2. Emory University School of Medicine Atlanta Georgia

3. Samuel Oschkin Comprehensive Cancer Institute Los Angeles California

4. Dana‐Farber/Boston Children's Cancer and Blood Disorders CenterHarvard Medical School Boston Massachusetts

5. Center for Cancer and Blood DisordersPhoenix Children's Hospital Phoenix Arizona

6. Division of Pediatric Hematology/Oncology and Bone Marrow TransplantationNemours Children's Specialty Care and Wolfson Children's Hospital Jacksonville Florida

Funder

National Institutes of Health

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28134

Reference45 articles.

1. Rapamune (Sirolimus, Rapamycin): An Overview and Mechanism of Action

2. Mechanism of action of rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells

3. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway